POET-II Trial Reveals Shorter Antibiotic Regimens for Endocarditis
New findings from the POET-II trial suggest that tailored antibiotic therapy can safely reduce treatment duration for infective endocarditis.
The POET-II trial indicates that a response-tailored approach can reduce antibiotic duration by 15 days without compromising safety.
Results show that 50% of patients with left-sided infective endocarditis may benefit from shorter treatment regimens.
Despite the benefits, caution is advised due to a higher relapse rate in tailored therapy for certain infections.
The POET-II trial has recently presented groundbreaking findings regarding antibiotic therapy duration for infective endocarditis (IE) at the ESC Congress 2026. Conducted across 13 centers in Denmark, Sweden, and the USA, this randomized clinical trial aimed to determine whether a tailored approach to antibiotic treatment could effectively reduce the duration of therapy for patients with left-sided IE. The trial involved 508 adult patients who had already undergone 2–4 weeks of standard antibiotic treatment and met specific clinical stabilization criteria.
Historically, the treatment for IE has relied on prolonged intravenous antibiotic therapy lasting up to six weeks, as endorsed by major health organizations like the American Heart Association and the European Society of Cardiology. However, the POET trial in 2018 began to challenge this norm by suggesting that patients could safely transition to oral antibiotics after 10 days of intravenous treatment. The POET-II trial builds on this foundation, investigating whether the total duration of antibiotic therapy could be personalized based on individual clinical responses rather than adhering to a fixed schedule.
In the POET-II trial, participants were randomized into two groups: one that continued standard antibiotic therapy for 4-6 weeks and another that discontinued antibiotics immediately after meeting stabilization criteria. The results indicated that the tailored therapy group experienced a mean of 183 days without antibiotic treatment, compared to 169 days in the standard therapy group, demonstrating a significant improvement. Additionally, the safety outcomes were comparable, with 8% of patients in the tailored group experiencing adverse events compared to 11% in the standard group.
The implications of these findings are substantial, as they suggest that nearly half of the patients with left-sided IE might qualify for shorter, tailored antibiotic regimens. This shift could lead to fewer side effects and reduced healthcare costs, addressing a long-standing treatment paradigm that has remained largely unchallenged for decades. However, the trial also highlighted a higher incidence of relapse in the tailored therapy group, particularly among those infected with specific pathogens, indicating the need for careful patient selection and management.
Looking ahead, the POET-II trial encourages clinicians to rethink antibiotic therapy duration for infective endocarditis, advocating for a more personalized approach. As the medical community processes these findings, further research will be essential to refine treatment protocols and ensure patient safety while optimizing therapeutic outcomes.
